2024.03.19 (화)

  • 구름조금동두천 5.9℃
  • 구름많음강릉 6.3℃
  • 구름조금서울 6.9℃
  • 구름많음대전 6.0℃
  • 맑음대구 10.7℃
  • 맑음울산 11.4℃
  • 황사광주 7.0℃
  • 맑음부산 12.0℃
  • 구름조금고창 5.7℃
  • 황사제주 10.8℃
  • 구름조금강화 5.3℃
  • 맑음보은 6.2℃
  • 구름조금금산 5.7℃
  • 맑음강진군 8.1℃
  • 맑음경주시 11.3℃
  • 맑음거제 11.2℃
기상청 제공

경제

Neos Therapeutics Announces Issuance of New Patent Covering Composition of Matter for Company’s Novel ADHD Products

[By NBC-1TV H. J Yook] Neos Therapeutics, Inc. (“Neos” or “the Company”), a highly differentiated oral drug delivery company with a portfolio of proprietary technologies and a late-stage pipeline of innovative controlled release (CR) products for ADHD, announced today that it has been granted a patent covering its novel amphetamine ADHD products.

Neos has developed an extended release (XR) amphetamine oral disintegrating tablet (ODT) and an extended release amphetamine liquid suspension both of which are expected to be filed for FDA approval in the next 12-15 months. “We are pleased with the grant of this patent as it will provide protection for our amphetamine XR-ODT and amphetamine XR-suspension until June 2032,” said Vipin K. Garg, Ph.D., Chief Executive Officer of Neos. “We have begun to assess our options to commercialize these products in anticipation of FDA approval.”

“The Neos patent portfolio continues to grow as we continue to develop and utilize our platform drug delivery technologies,” stated Mark Tengler, Chief Technology Officer of Neos. “Extended release and patient-friendly dosage forms are essential in the treatments of ADHD, and our technologies may provide this advantage.”



배너

관련기사


배너
배너
배너
배너
배너
배너
배너
배너
배너
배너